KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$2.2 billion.

  • Ionis Pharmaceuticals' Enterprise Value rose 978.97% to -$2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 billion, marking a year-over-year increase of 978.97%. This contributed to the annual value of -$2.3 billion for FY2024, which is 143.9% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Enterprise Value stood at -$2.2 billion for Q3 2025, which was up 978.97% from -$2.3 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Enterprise Value ranged from a high of -$1.8 billion in Q1 2021 and a low of -$2.5 billion during Q3 2024
  • Over the past 5 years, Ionis Pharmaceuticals' median Enterprise Value value was -$2.1 billion (recorded in 2025), while the average stood at -$2.2 billion.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Enterprise Value skyrocketed by 1628.03% in 2021, and later plummeted by 1798.18% in 2023.
  • Ionis Pharmaceuticals' Enterprise Value (Quarter) stood at -$2.1 billion in 2021, then rose by 6.06% to -$2.0 billion in 2022, then fell by 17.33% to -$2.3 billion in 2023, then rose by 1.44% to -$2.3 billion in 2024, then grew by 2.5% to -$2.2 billion in 2025.
  • Its Enterprise Value was -$2.2 billion in Q3 2025, compared to -$2.3 billion in Q2 2025 and -$2.1 billion in Q1 2025.